Legal Weed Wildcard #1 Teva Pharmaceutical Ind
Post# of 15624
(Total Views: 814)
Posted On: 03/07/2017 6:48:24 PM
Legal Weed Wildcard #1
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA), out of Israel, manufactures, markets,
and distributes generic and specialty medicines worldwide. It is currently the world’s largest maker of
“generic” drugs.
Teva has signaled that it wants in on marijuana.
In July of 2015 Teva announced that it planned to acquire rival Allergan Generics for $40.5 billion dollars.
The move made perfect sense. Copaxone, Teva’s lead drug, is going off patent. That means generic
equivalents can be developed and sold, which will siphon away much of the $3.29 billion in revenue
Teva hoped to earn from Copaxone this year. Buying the generic drug maker would help offset some of
those losses.
Teva made another announcement last July that garnered less attention from the press.
The company revealed that it had made a bid to acquire the patents of another Israeli firm, One World
Cannabis (OWC).
One World Cannabis (a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTC:
OWCP)) conducts research and clinical trials into cannabis-based products to treat multiple myeloma,
psoriasis, fibromyalgia, PTSD, migraines, and other ailments.
Again, the move makes perfect sense. To offset declining revenue as its lead drug loses patent
protection,
Teva is looking to expand into medical marijuana.
OWC is still in the early stages of drug development, but it has produced some promising results.
According to online news site The Marker, “OWC recently reported a study by the Sheba Medical
Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment
using the cannabis plant’s active ingredients.”
Nothing hurts a drug-makers top line as much as having its lead drug go off patent. So expect more
and more Big Pharma players to begin exploring ways to leverage legal cannabis to replace some of
that revenue.
Teva Pharmaceutical has already made an “opening gambit.”
There are other signs that that the Israeli giant is taking a good look at medical marijuana
OWCP is well suited for an unlimited Global Growth in MMJ -Pharma
According to the U.S. Census
Bureau, by 2030 one fifth of
the population – 72 million
Americans – will be 65 or older.
Those Baby Boomers will all
confront a slew of age-related
ailments, such as glaucoma,
cancer, arthritis and back pain.
As it happens, cannabis-based
remedies are uniquely suited to
treating those diseases.
So as the elderly population
grows, so will the size of the
medical marijuana market.
Social acceptance of cannabis
will grow as well, as millions of
people discover the benefits
of medical marijuana for themselves.
LEGAL WEED IS AN UNSTOPPABLE GLOBAL TREND
America is far from the only country poised to loosen the reins on marijuana.
Here are nine countries that are leading the way.
Israel – Has already approved a wide array of cannabis-based treatments for cancer, epilepsy
and MS.
Canada – A full legalization program is currently being developed, with the explicit approval
and support of Prime Minister Justin Trudeau.
Spain – Citizens can grow and consume cannabis; they are forbidden from transporting or
selling it.
Mexico – Cannabis is decriminalized, but President Enrique Peña Nieto opposes a fully-legal
cannabis market.
Australia – According to ArcView, “On October 17, 2015 the Federal Government announced
that it would legalize the growing of cannabis for medicinal and scientific purposes.”
Uruguay – Became the first country ever to legalize the sale of marijuana, but so far the legal
market lags behind the “homegrown” market.
Jamaica – Has decriminalized possession of up to two ounces of cannabis, and now regulates
cultivation for medical and religious purposes.
Germany – Possession is illegal, but consumption is legal. Also, scientific institutions can
cultivate and possess cannabis, and pharmacies can sell cannabis-based treatments with
government permission.
Colombia – Since 1994, possession of up to 22 grams for personal use has been legal. On
December 22, 2015, President Juan Manuel Santos signed a decree “legalizing the cultivation,
consumption, export, and import of cannabis strictly for medical and scientific purposes,”
according to ArcView.
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA), out of Israel, manufactures, markets,
and distributes generic and specialty medicines worldwide. It is currently the world’s largest maker of
“generic” drugs.
Teva has signaled that it wants in on marijuana.
In July of 2015 Teva announced that it planned to acquire rival Allergan Generics for $40.5 billion dollars.
The move made perfect sense. Copaxone, Teva’s lead drug, is going off patent. That means generic
equivalents can be developed and sold, which will siphon away much of the $3.29 billion in revenue
Teva hoped to earn from Copaxone this year. Buying the generic drug maker would help offset some of
those losses.
Teva made another announcement last July that garnered less attention from the press.
The company revealed that it had made a bid to acquire the patents of another Israeli firm, One World
Cannabis (OWC).
One World Cannabis (a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTC:
OWCP)) conducts research and clinical trials into cannabis-based products to treat multiple myeloma,
psoriasis, fibromyalgia, PTSD, migraines, and other ailments.
Again, the move makes perfect sense. To offset declining revenue as its lead drug loses patent
protection,
Teva is looking to expand into medical marijuana.
OWC is still in the early stages of drug development, but it has produced some promising results.
According to online news site The Marker, “OWC recently reported a study by the Sheba Medical
Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment
using the cannabis plant’s active ingredients.”
Nothing hurts a drug-makers top line as much as having its lead drug go off patent. So expect more
and more Big Pharma players to begin exploring ways to leverage legal cannabis to replace some of
that revenue.
Teva Pharmaceutical has already made an “opening gambit.”
There are other signs that that the Israeli giant is taking a good look at medical marijuana
OWCP is well suited for an unlimited Global Growth in MMJ -Pharma
According to the U.S. Census
Bureau, by 2030 one fifth of
the population – 72 million
Americans – will be 65 or older.
Those Baby Boomers will all
confront a slew of age-related
ailments, such as glaucoma,
cancer, arthritis and back pain.
As it happens, cannabis-based
remedies are uniquely suited to
treating those diseases.
So as the elderly population
grows, so will the size of the
medical marijuana market.
Social acceptance of cannabis
will grow as well, as millions of
people discover the benefits
of medical marijuana for themselves.
LEGAL WEED IS AN UNSTOPPABLE GLOBAL TREND
America is far from the only country poised to loosen the reins on marijuana.
Here are nine countries that are leading the way.
Israel – Has already approved a wide array of cannabis-based treatments for cancer, epilepsy
and MS.
Canada – A full legalization program is currently being developed, with the explicit approval
and support of Prime Minister Justin Trudeau.
Spain – Citizens can grow and consume cannabis; they are forbidden from transporting or
selling it.
Mexico – Cannabis is decriminalized, but President Enrique Peña Nieto opposes a fully-legal
cannabis market.
Australia – According to ArcView, “On October 17, 2015 the Federal Government announced
that it would legalize the growing of cannabis for medicinal and scientific purposes.”
Uruguay – Became the first country ever to legalize the sale of marijuana, but so far the legal
market lags behind the “homegrown” market.
Jamaica – Has decriminalized possession of up to two ounces of cannabis, and now regulates
cultivation for medical and religious purposes.
Germany – Possession is illegal, but consumption is legal. Also, scientific institutions can
cultivate and possess cannabis, and pharmacies can sell cannabis-based treatments with
government permission.
Colombia – Since 1994, possession of up to 22 grams for personal use has been legal. On
December 22, 2015, President Juan Manuel Santos signed a decree “legalizing the cultivation,
consumption, export, and import of cannabis strictly for medical and scientific purposes,”
according to ArcView.
(0)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼